Because MM cells with high proteasomal activity relied on DDI2 for survival upon treatment with BTZ, we investigated the contribution of the DDI2-NRF1 pathway to proteasome activity at basal and upon treatment with BTZ. This evidence concerns the gene DDI2 and Miyoshi myopathy.